NPCE — Neuropace Cashflow Statement
0.000.00%
Last trade - 00:00- $365.03m
- $371.80m
- $79.91m
- 46
- 13
- 94
- 50
Annual cashflow statement for Neuropace, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -24.3 | -36.1 | -47.1 | -33 | -27.1 |
| Depreciation | |||||
| Non-Cash Items | 4.42 | 10.8 | 12 | 14.1 | 12.9 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -2.07 | 0.368 | -4.79 | -2.48 | -5.45 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -21.6 | -24.6 | -36.9 | -19.7 | -17.9 |
| Capital Expenditures | -0.062 | -0.384 | -0.603 | -0.173 | -0.306 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -10.7 | -85 | 24.4 | 23.2 | 9.3 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -10.8 | -85.4 | 23.8 | 23 | 8.99 |
| Financing Cash Flow Items | -1.16 | -3.39 | -0.406 | -0.564 | -0.881 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 55 | 103 | 0.49 | 8.13 | 4.33 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 22.6 | -7.45 | -12.6 | 11.5 | -4.63 |